- Conditions
- Refractory Hematologic Cancer
- Interventions
- Cdc7-inhibitor (BMS-863233)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- Miami, Florida • Tampa, Florida • Boston, Massachusetts + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 5,764
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- naltrexone, PET scan
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Glioblastoma Multiforme
- Interventions
- Bevacizumab, BKM120
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Fort Myers, Florida • Orlando, Florida + 5 more
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab with Chemotherapy
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
- Conditions
- Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma
- Interventions
- Ipilimumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • New York, New York
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor, Malignant Tumor of Breast, Advanced Breast Cancer, Advanced Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration-resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Glioblastoma, Recurrent Glioblastoma
- Interventions
- NUV-422
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more
- Conditions
- Bony Metastases From Castrate Refractory Prostate Cancer
- Interventions
- Radium-223 dichloride
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Venetoclax
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
- Drug · Radiation · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- fenretinide
- Drug
- Lead sponsor
- California Cancer Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- veliparib, pharmacological study, biopsy
- Drug · Other · Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neoplasms, Breast
- Interventions
- lapatinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 8
- States / cities
- Miami, Florida • Chicago, Illinois • Zion, Illinois + 5 more
- Conditions
- Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Palbociclib, Dexamethasone, Lenalidomide
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cixutumumab, pharmacological study, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- entinostat, sargramostim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Neuroblastoma, Refractory Neuroblastoma
- Interventions
- Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
- Conditions
- Lymphoma
- Interventions
- romidepsin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Detroit, Michigan + 1 more
- Conditions
- Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Interventions
- Tegavivint, Gemcitabine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Houston, Texas
- Conditions
- Meningioma, Meningioma, Adult
- Interventions
- Avelumab, Proton Therapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma
- Interventions
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
- Biological · Drug
- Lead sponsor
- Imugene Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more
- Conditions
- Choriocarcinoma
- Interventions
- TRC105, Bevacizumab
- Biological
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
- Interventions
- revumenib, cobicistat
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 30 Days and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 22
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 17 more